Heptin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Heptin

What is Heptin? (Composition: Heparin)

Property Description
Active ingredient Heparin Sodium (Unfractionated Heparin)
Form Sterile liquid solution
Pharmacological class Anticoagulant (Blood thinner)
Common use Inhibition of blood clotting
Origin Naturally derived (Purified from animal tissue)

Heptin is a single-active-ingredient medication whose component, Heparin Sodium, is classified by authoritative bodies as a potent anticoagulant (often described as a blood thinner). This pharmaceutical preparation belongs to the class of Unfractionated Heparins (UFH) and functions as a fast-acting agent to manage the body’s blood clotting system. It is administered via parenteral routes, such as intravenous injection or infusion, as the large compound cannot be absorbed effectively if taken orally.


What Type of Medicine is Heptin?

Heptin is a preparation whose active substance, Heparin, is clinically recognized for its essential role in managing coagulation. Its effectiveness stems from its active component, Heparin Sodium, a complex sulfated glycosaminoglycan. The core action involves greatly enhancing the ability of a natural plasma protein, Antithrombin III, to quickly inactivate key clotting enzymes in the blood, particularly thrombin (Factor IIa) and Factor Xa, thus preventing the formation of a stable clot. This mechanism provides an immediate, highly controllable anticoagulant effect.


Is Heparin Naturally Derived?

The Heparin active ingredient in Heptin is naturally derived; it is purified and extracted from animal tissues, most commonly the porcine intestinal mucosa. This biological origin results in a heterogeneous mixture of molecules, classifying it as Unfractionated Heparin (UFH). Heptin is supplied as a sterile liquid solution for injection or infusion, intended for acute care settings or as a low-concentration lock flush solution used to maintain the patency (openness) of intravenous catheters.


What is the General Goal of Heptin?

The general purpose of Heptin is to provide immediate inhibition of blood clotting to ensure that blood remains free-flowing in the circulatory system. This rapid, potent anticoagulant activity is necessary in acute medical situations where the formation of unwanted blood clots presents a significant risk. The medication prevents new clots from forming and stops existing clots from growing larger, allowing the body's natural processes to gradually manage the existing thrombi.

Regulatory References

  1. NIH National Library of Medicine - MedlinePlus Drug Information (Heparin)

What side effects are possible with Heptin?

Possible side effects and safety information

The official safety information for Heparin Sodium, the active ingredient in Heptin, establishes a structured profile of documented adverse reactions, frequency classifications, and population-specific considerations. The medicine's primary safety concern, which is the most common adverse reaction, is Hemorrhage (bleeding), and this risk may range from minor occurrences to serious or fatal events, as detailed in regulatory documents.

Hematological and Immunological Effects

Adverse reactions involving the blood system are officially listed, notably Thrombocytopenia (low platelet count), which is frequently observed. A specific, serious, immune-mediated complication is Heparin-Induced Thrombocytopenia with Thrombosis (HITT). This reaction is explicitly noted for its potential to cause severe clotting events, such as stroke, myocardial infarction, or skin necrosis, and can occur either rapidly or be delayed up to several weeks after administration.

Other adverse reactions that have been officially documented span several system-organ classes, including Hypersensitivity Reactions (e.g., fever, urticaria), elevations of aminotransferase levels (a sign of liver changes), and local irritation at the injection site. Changes in electrolyte balance, such as Hyperkalemia (elevated potassium), and the development of Osteoporosis (bone loss) associated with long-term, high-dose exposure are also part of the documented safety profile.

Population and Duration Notes

Regulatory safety information notes specific considerations for certain groups. An increased incidence of bleeding has been reported for older patients, particularly women over 60 years of age. For neonates and infants, preservative-free formulations are recommended to mitigate the risk of Benzyl Alcohol Toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

Heptin (Heparin Sodium) overdose is primarily identified by signs of bleeding, which is the chief symptom due to excessive anticoagulant effects. Overdoses have been reported due to medication errors, including the use of incorrect strengths, and can lead to potentially life-threatening hemorrhage.

Signs of Overdose

The principal symptoms of overdosage relate to bleeding and may include:

  • Easy bruising or petechial formations
  • Nosebleeds
  • Blood in urine
  • Black or tarry stools
  • Any persistent, unexplained bleeding

When Immediate Medical Attention is Required

An overdose requires immediate medical attention and treatment. It is essential to seek emergency medical care at once if any signs of serious bleeding are observed. Certain patients, particularly women over 60 years of age, are noted in official labeling to have a higher reported incidence of bleeding, which underscores the need for close monitoring in this population.

Emergency Treatment Information

Treatment for symptomatic overdose generally involves stopping the infusion and may require the administration of protamine sulfate. This agent acts to neutralize the effect of Heptin. Because the administration of protamine sulfate itself carries a risk of serious, potentially fatal reactions resembling anaphylaxis, it is given only when resuscitation equipment and treatments for anaphylactoid shock are immediately available.

Therapeutic Uses of Heptin

What Heptin Treats: Main Uses and Benefits

Heptin is a relevant treatment applied across therapeutic domains involving acute or disruptive symptom patterns caused by unwanted blood clot formation. Its use covers the acute care management of established clots, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), as well as providing protection against the sudden formation of new clots in high-risk scenarios. This short-term preventative use plays a role in protection against clots following major surgery or during severe Acute Coronary Syndromes.

The medication is commonly used to manage clot risk associated with Atrial Fibrillation and plays a supportive role during specialized procedures like hemodialysis and cardiac surgery. The primary benefit is providing timely anticoagulation to inhibit the existing clot from growing larger, which generally helps ease the acute swelling and pain and supports the patient's stability.


“Heptin assists with maintaining functional stability by supporting the continuity of important care procedures.”


Quick Fact: Relief for Acute Circulatory Symptoms
Therapeutic Focus: Timely assistance in managing the clotting process in acute situations.
Symptom Management: Helps ease symptoms related to acute swelling and localized pain in thrombotic conditions.
Context: Commonly used when systemic physiological stress or immobility leads to a heightened risk of clot formation.

Regulatory References

  1. U.S. Food and Drug Administration Drug Label via DailyMed

Eligibility and Restrictions for Use

Official Eligibility and Restrictions

Regulatory documents define specific populations who are permitted to use Heptin (Heparin Sodium), as well as groups for whom its use is absolutely prohibited or requires special caution.

Category Official Regulatory Status
Absolute Contraindications Prohibited in patients with an uncontrollable active bleeding state, a history of Heparin-Induced Thrombocytopenia (HIT), severe thrombocytopenia, or known hypersensitivity to heparin or pork products.
Conditional Use (Caution) Required in conditions that increase the risk of hemorrhage, such as severe hypertension, Subacute Bacterial Endocarditis, or ulcerative gastrointestinal lesions. Use is also cautioned in patients with conditions predisposing to hyperkalemia or those taking potassium-sparing drugs.
Age-Related Rules Neonates and Infants must use a preservative-free formulation; the preservative Benzyl Alcohol is not recommended for this group. Caution is advised for older adults (over 60), particularly women, due to a reported higher risk of bleeding.
Pregnancy/Lactation Preservative-free formulations are recommended during pregnancy. For lactation, females are advised not to breastfeed.
Monitoring Requirement Full-dose use is contraindicated if suitable blood coagulation tests cannot be performed at appropriate intervals for regulation.

What should I know about interactions with other medicines?

Heptin (Heparin Sodium) has an interaction profile primarily characterized by pharmacodynamic (PD) effects with other medicines that affect the blood coagulation system. Co-administration with platelet inhibitors, including NSAIDs and Aspirin, or other injectable and oral anticoagulants, may result in the amplification of bleeding risk by interfering with platelet function. Certain non-anticoagulant products, such as Digitalis, Tetracyclines, Nicotine, and Intravenous Nitroglycerin, are documented to partially counteract the anticoagulant action.

Some regulatory authorities specify combination constraints, such as the formal prohibition of co-administration with Intravenous Diclofenac. Additionally, the concurrent presence of severe thrombocytopenia constitutes a documented interaction-related restriction. For patients transitioning to or monitoring oral anticoagulants like warfarin, official regulatory documents mandate a timing rule: blood must be drawn at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose of Heptin to yield a valid prothrombin time result. The primary interaction risk of bleeding is formally noted as having a higher incidence in older patients, particularly women over 60, and in those with underlying liver disease with impaired hemostasis.

Mechanism of Action

How Heptin Works

Catalysis of Antithrombin III

Heptin's active ingredient, Unfractionated Heparin (UFH), works by accelerating the inhibitory action of Antithrombin III (ATIII), a natural protein in the blood. . The drug binds to ATIII and acts as a catalyst, significantly increasing its rate of neutralization of key clotting enzymes (up to 1,000-fold). This molecular acceleration defines the mechanism's high speed and systemic nature.

Interruption of the Coagulation Cascade

The activated Heparin-ATIII complex directly targets two central enzymes in the common coagulation pathway: Factor Xa and Thrombin (Factor IIa). By neutralizing these factors, the drug effectively blocks the chemical sequence that leads to the final conversion of soluble fibrinogen into the insoluble fibrin mesh. This molecular blockade results in the physiological action of inhibiting the formation of stable thrombi.

Mechanistic Constraints

The drug’s activity exhibits greatest affinity for circulating factors and is less effective against thrombin already bound to fibrin within an established clot. Furthermore, the drug’s function can be neutralized by Platelet Factor 4 (PF4), a protein released by activated platelets, which binds to Heparin and functionally removes it from the plasma.

Dosage and Administration Information

Official Administration Guidelines for Heptin

Heptin (Heparin Sodium) is administered solely by the parenteral route, primarily via Intravenous (IV) Injection or Continuous IV Infusion. It is not for intramuscular use. The dosage is highly individualized and must be adjusted according to the patient's coagulation test results, particularly the Activated Partial Thromboplast Time (APTT), to achieve a therapeutic range (typically 1.5 to 2 times the control value).


Dosing Schedule and Frequency

Administration Method Initial Dose (Adult, approx. 68 kg) Maintenance Dose & Frequency
Intermittent IV Injection 10,000 units 5,000–10,000 units every 4 to 6 hours
Continuous IV Infusion 5,000 units IV bolus 20,000–40,000 units per 24 hours in a compatible diluent

For major cardiovascular surgery, a starting dose of ge 150 units/kg via total body perfusion is required. Timing in relation to meals is not applicable for the IV route.

Procedural Requirements

Preparation: Inspect the solution visually for particulate matter or discoloration; use only if the solution is clear and the seal is intact. For continuous infusion, the container must be inverted repeatedly to ensure adequate mixing and prevent pooling.

Monitoring: Coagulation tests, such as APTT, must be determined approximately every 4 hours during the early stages of continuous infusion therapy, or before each injection during the early stages of intermittent IV treatment.

Age-Specific Use: The official documentation notes that pediatric use requires age-specific dosing rules, and preservative-free formulations are recommended for neonates and infants.

Missed Dose: If a scheduled dose is missed, patients should contact their healthcare professional for instructions. Do not administer a double dose to compensate for the missed one.


Summary: The official use protocol for Heptin is a strictly monitored, continuous or timed IV administration regimen. The dose is dynamic, requiring frequent laboratory testing to guide and adjust the rate or amount administered to maintain the specified therapeutic effect.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Heptin (Unfractionated Heparin)

Evidence for Use in Acute Venous Thromboembolism (VTE)

Research into Heptin (Unfractionated Heparin or UFH) was evaluated in numerous Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses for its role in conditions characterized by acute or disruptive episodes of clotting, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). These studies primarily focused on outcomes related to systemic or functional imbalance caused by the clot itself. The core body of research explored the use of anticoagulation and monitored specific outcomes. Studies monitored outcomes related to clot extension and recurrent VTE events in the observed populations during studies comparing UFH to no anticoagulation. Research has explored the use of UFH in the acute treatment research landscape.

Evidence for Use in Acute Coronary Syndromes (ACS)

Heptin was evaluated in research exploring its function during acute cardiac events, including certain types of heart attack or Acute Coronary Syndromes (ACS). Research explored the use of UFH as a procedural tool during invasive interventions like stenting or catheterization. The studies explored physiological strain and tracked the rate of adverse cardiovascular events associated with clot formation. The findings describe patterns related to blood flow that were observed when UFH was evaluated for its procedural role in conditions associated with acute or disruptive episodes. Study results reflect the specific conditions under which they were conducted, which often included UFH being used in combination with several other antithrombotic medicines.

What Remains Uncertain About Heptin's Research

Scientific literature describes several uncertainties within the research landscape for UFH. Comparative evidence is lacking in some areas where UFH is currently compared to other, newer anticoagulants. Sample sizes were modest in some earlier studies, and achieving a standardized monitoring approach is consistently noted as a challenge. Evidence highlights what is known — and what is still uncertain, stressing that ongoing research is necessary to refine protocols. Follow-up durations were limited in many core trials, and dedicated long-term research is rare, meaning there is limited information for long-term outcomes.

Key Studies & References

  1. Heparin Sodium (Injection Route) - MedlinePlus Drug Information
  2. Heparin Sodium Injection, USP (Drug Label) - U.S. Food and Drug Administration Drug Label via DailyMed

Frequently Asked Questions (FAQ)

Common questions about Heptin (FAQ)

Q: What are the most commonly reported side effects of Heptin?

The primary adverse reaction reported in official product information is Hemorrhage (bleeding), which can range from minor to serious. Officially documented reactions also include thrombocytopenia (low platelet count), changes in liver function tests, and localized reactions or pain at the site of administration.

Q: Can Heptin cause stomach issues or nausea?

Regulatory documents list gastrointestinal symptoms such as nausea and vomiting as potential, though less common, adverse reactions. These effects may sometimes be associated with general hypersensitivity reactions to the medication.

Q: Does Heptin make you feel sleepy or dizzy?

Official information lists dizziness as a symptom that may be associated with serious side effects, such as bleeding or allergic reaction. If dizziness is experienced, it may warrant immediate contact with a healthcare provider. Sleepiness or general sedation is not typically listed as a common side effect of Heptin.

Q: Is it normal to feel a bit tired when starting Heptin?

Official patient guidance states that unusual tiredness (fatigue) can be a serious symptom that may signal internal bleeding, a major safety concern with this type of medication. If unusual fatigue is noted, it is important to discuss this with a healthcare professional.

Q: Can Heptin interact with over-the-counter pain relievers like ibuprofen?

Yes, official regulatory guidance warns that taking Heptin with other platelet inhibitors, including NSAIDs like ibuprofen, may significantly increase the risk of bleeding. The combination of these medicines requires careful clinical monitoring.

Q: Can Heptin be taken with vitamin supplements?

Official regulatory guidance advises patients to inform their health care provider about all products they are using, including over-the-counter medicines, vitamins, herbal products, and other supplements. It is important for patients to discuss these products because they may potentially interfere with Heptin’s action.

Q: Does Heptin interact with blood pressure medications?

Heptin can cause an increase in the body's potassium level, a condition called hyperkalemia. Official warnings state that caution is required when it is used alongside other medications that can also raise potassium, such as certain diuretics or specific blood pressure medicines.

Q: How quickly does Heptin start working?

Heptin (Heparin) is classified as a fast-acting anticoagulant. When administered intravenously, as is typically the case, it provides an immediate onset of action. This rapid effect is necessary for managing acute, high-risk clotting situations.

Q: Is Heptin the same as other similar-sounding medications?

Heptin’s active component is Unfractionated Heparin (UFH). While other medications like Low Molecular Weight Heparins (LMWH) have a similar basis, UFH has a unique chemical structure and requires different clinical monitoring and administration methods.

Q: Are there any serious side effects of Heptin I should know about?

Yes, the two most serious risks outlined in regulatory documents are severe Hemorrhage (bleeding) and an immune-mediated complication called Heparin-Induced Thrombocytopenia with Thrombosis (HITT). HITT is a rare but severe clotting disorder that can potentially lead to stroke, heart attack, or other fatal clotting events.

Q: What is the average duration of treatment with Heptin?

The duration of treatment is highly individualized and depends entirely on the condition being treated and the patient's specific needs. For preventing post-operative clots, for example, official information states that treatment is often continued for at least seven days or until the patient is fully mobile.

Q: Does Heptin affect mood or anxiety levels?

While not listed as a common side effect, anxiety is included in official adverse event reports and patient guidance. If experienced alongside symptoms like difficulty breathing or chest pain, anxiety may signal a serious complication that should be reported to a healthcare provider promptly.

Q: Why do doctors often prescribe Heptin?

Heptin is typically prescribed because it provides a rapid and highly controllable anticoagulant effect. This makes it an essential tool for preventing blood clots in high-risk patients and for acutely treating existing clots related to conditions like Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

Q: What is the long-term safety profile of Heptin?

The long-term safety profile, according to regulatory documents, notes that long-term, high-dose exposure is associated with an increased risk of developing Osteoporosis (bone loss). The risk of bleeding is also noted to be higher in older patients, particularly women over the age of 60.

Q: What should I do if I experience an allergic reaction to Heptin?

If signs of a severe allergic reaction are observed (such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), regulatory guidance indicates the need for immediate emergency medical evaluation.

Q: Does Heptin require routine blood tests for monitoring?

Yes, when Heptin is used at full therapeutic doses, frequent blood tests are required. Specifically, tests like the Activated Partial Thromboplastin Time (APTT) are used to ensure the amount of medication in the blood remains within the therapeutic range needed for safety and effectiveness.

Q: What are the signs that Heptin is working for me?

The effectiveness of Heptin is primarily assessed by the healthcare team through frequent laboratory blood tests, such as APTT. For the patient, the goal is the prevention of new clot formation or growth, which may be reflected by the resolution of symptoms related to the condition being treated.

Q: Is it possible for Heptin to stop working over time?

While generally uncommon, regulatory documents acknowledge a rare phenomenon known as Heparin Resistance. This is defined as a lack of therapeutic response to Heptin, which would be identified through the monitoring blood tests.

Q: What are the common reasons people discontinue Heptin treatment?

Official guidance mandates that Heptin must be discontinued promptly if a serious adverse event occurs. The main reasons for discontinuation are confirmed, uncontrollable bleeding/hemorrhage or a diagnosis of Heparin-Induced Thrombocytopenia (HIT).

Q: Are there specific symptoms that signal a need to contact a doctor about Heptin side effects?

Official patient information notes that symptoms such as unusual or excessive bruising, bloody or black/tarry stools, blood in the urine, or sudden, severe pain or swelling may signal a need for immediate discussion with a healthcare provider. These symptoms may relate to the primary safety concern of bleeding.

How should Heptin be stored and disposed of?

Storage and Disposal Requirements for Heptin (Heparin Sodium)

The storage and disposal of Heptin must strictly follow the conditions specified in official regulatory documents to maintain the stability of the sterile liquid solution.

Storage Conditions

  • Temperature: Store the medication at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). Do Not Freeze.
  • Protection: The vial must be kept in the original carton to protect the contents from light.
  • Child Safety: The product must be stored out of the sight and reach of children.

Stability and Disposal

  • Post-Puncture Stability: Multiple-dose vials are stable for up to 28 days after the first entry. Single-dose vials must be discarded immediately after a single use.
  • Disposal: Unused or expired medication must be disposed of according to local requirements for medical waste and should not be discarded in household trash or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Heptin found in:

A-Z Index: